Zhejiang CONBA Pharmaceutical Co Ltd
SSE:600572
Zhejiang CONBA Pharmaceutical Co Ltd
EPS (Diluted)
Zhejiang CONBA Pharmaceutical Co Ltd
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Zhejiang CONBA Pharmaceutical Co Ltd
SSE:600572
|
EPS (Diluted)
¥0
|
CAGR 3-Years
11%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-2%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
EPS (Diluted)
¥0
|
CAGR 3-Years
18%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
EPS (Diluted)
¥5
|
CAGR 3-Years
9%
|
CAGR 5-Years
18%
|
CAGR 10-Years
24%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
EPS (Diluted)
¥1
|
CAGR 3-Years
12%
|
CAGR 5-Years
4%
|
CAGR 10-Years
15%
|
|
|
C
|
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
|
EPS (Diluted)
¥0
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
EPS (Diluted)
-¥1
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Zhejiang CONBA Pharmaceutical Co Ltd
Glance View
Zhejiang CONBA Pharmaceutical Co., Ltd. stands as a prominent figure in the vast landscape of China's pharmaceutical industry. This enterprise, established in the economically vibrant province of Zhejiang, has carved its niche through rigorous adherence to research-driven innovation and quality assurance. While the pharmaceutical realm is competitive and challenging, CONBA has made strategic inroads by focusing on both modern medicine and traditional Chinese medicine (TCM). This dual approach has allowed the company to tap into a rich tapestry of healthcare solutions, catering to diverse consumer needs. By leveraging a robust research and development framework, CONBA continues to enhance its portfolio, offering a wide array of medicinal products including prescription drugs, over-the-counter medications, and healthcare supplements. Financially, Zhejiang CONBA thrives through a multifaceted business model. The company's revenue streams are bolstered by its strong domestic market presence alongside its expanding international footprint. It strategically combines manufacturing prowess with an extensive distribution network, ensuring that its products are readily accessible. Moreover, CONBA's commitment to quality and compliance with international regulatory standards has fostered trust and reinforced its brand reputation both within and outside of China. As it continues to evolve, CONBA remains dedicated to harnessing advancements in biotechnology and pharmacology, aiming to sustain profitability while contributing to the global healthcare dialogue.
See Also
What is Zhejiang CONBA Pharmaceutical Co Ltd's EPS (Diluted)?
EPS (Diluted)
0.2
CNY
Based on the financial report for Sep 30, 2024, Zhejiang CONBA Pharmaceutical Co Ltd's EPS (Diluted) amounts to 0.2 CNY.
What is Zhejiang CONBA Pharmaceutical Co Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
-2%
Over the last year, the EPS (Diluted) growth was -34%. The average annual EPS (Diluted) growth rates for Zhejiang CONBA Pharmaceutical Co Ltd have been 11% over the past three years , -1% over the past five years , and -2% over the past ten years .
You don't have any saved screeners yet